Q-omics provides the consensus-scored TMEM18 profile across patient tissues and cancer cell-line models. TMEM18 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TMEM18 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, TMEM18 RNA expression shows 19,859 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where TMEM18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM18 survival associations across molecular data types. TMEM18 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM18 RNA expression–survival associations across cancer types. High TMEM18 expression shows unfavorable associations in ACC, KICH, LIHC and KIRP, but favorable associations in KIRC and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TMEM18 RNA expression.
This table summarizes TMEM18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM18 shows lower tumor expression in THCA and KICH and higher tumor expression in KIRC, COAD, LIHC and HNSC. The KIRC box plot shows higher TMEM18 RNA expression in tumor versus normal tissue (log2 FC = +0.535, t-test p < 0.001).
This table shows molecular features associated with TMEM18 in patient tissues and cancer cell lines. In patient samples, TMEM18 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
